Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience announced promising top-line results from its HeROPA clinical study, showing that a larger percentage of patients treated with HRO350 achieved clear or almost clear skin compared to those on placebo. The company also secured NOK 30 million in long-term funding, which, along with cost-reduction measures, is expected to support its financial stability and growth. The nutraceutical business performed according to budget in Q1 2025, with plans to launch new products in Norway, Sweden, and China, and expand B2B operations. Arctic Algae, a group company, is progressing well with research projects. Financially, the company saw increased sales revenue and improved adjusted EBITDA, despite a slight dip in gross margin due to an extraordinary cost provision.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company specializing in the development and commercialization of pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is focused on creating innovative treatments like HRO350, an oral drug candidate for mild-to-moderate psoriasis, and markets nutraceuticals globally under the ROMEGA® brand.
Average Trading Volume: 92,173
Current Market Cap: NOK75.74M
See more data about 9TD stock on TipRanks’ Stock Analysis page.